FSA
LCTX icon

Fort Sheridan Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Fort Sheridan Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,177
Closed -$92.1K – 291
2025
Q4 		$92.1K Hold
55,177
– – 0.01% 266
2025
Q3 		$93.2K Hold
55,177
– – 0.01% 267
2025
Q2 		$50.1K Hold
55,177
– – 0.01% 251
2025
Q1 		$24.9K Hold
55,177
– – ﹤0.01% 247
2024
Q4 		$27.7K Buy
55,177
+23,000
+71% +$16.9K ﹤0.01% 245
2024
Q3 		$29.1K Hold
32,177
– – ﹤0.01% 247
2024
Q2 		$32.1K Hold
32,177
– – 0.01% 233
2024
Q1 		$47.6K Sell
32,177
-8,754
-21% -$9.93K 0.01% 204
2023
Q4 		$44.6K Sell
40,931
-43,000
-51% -$47.1K 0.01% 199
2023
Q3 		$99K Hold
83,931
– – 0.02% 191
2023
Q2 		$118K Buy
83,931
+10,000
+14% +$13.8K 0.03% 197
2023
Q1 		$111K Sell
73,931
-10,000
-12% -$14K 0.03% 189
2022
Q4 		$98.2K Hold
83,931
– – 0.03% 179
2022
Q3 		$95K Buy
83,931
+5,000
+6% +$7.34K 0.03% 178
2022
Q2 		$125K Buy
78,931
+3,000
+4% +$3.96K 0.04% 173
2022
Q1 		$117K Buy
75,931
+23,000
+43% +$35.7K 0.03% 179
2021
Q4 		$130K Buy
52,931
+5,000
+10% +$11.7K 0.04% 186
2021
Q3 		$121K Hold
47,931
– – 0.04% 183
2021
Q2 		$137K Buy
47,931
+3,000
+7% +$7.76K 0.05% 174
2021
Q1 		$106K Buy
+44,931
New +$108K 0.04% 158

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fort Sheridan Advisors's LCTX Position: Q1 2026 in Review

Fort Sheridan Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 55,177 shares — an estimated $92.1K sold.

Fort Sheridan Advisors first reported a position in LCTX in Q1 2021 and held it in 20 quarters. The position peaked at $137K in Q2 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Fort Sheridan Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fort Sheridan Advisors sold 55,177 Lineage Cell Therapeutics shares in Q1 2026, an estimated $92.1K.
  • Fort Sheridan Advisors first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 20 quarters.
  • Fort Sheridan Advisors's Lineage Cell Therapeutics position peaked at $137K in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Fort Sheridan Advisors's 13F filing for Q1 2026, filed 6 May 2026.